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Background: Hirudin is an anti-coagulation protein produced by the salivary glands of the medicinal leech
Hirudomedicinalis. It is a powerful and specific thrombin inhibitor. The novel recombinant hirudin, RGD-hirudin,
which contains an RGD motif, competitively inhibits the binding of fibrinogen to GPIIb/IIIa on platelets, thus
inhibiting platelet aggregation while maintaining its anticoagulant activity.
Results: Recombinant RGD-hirudin and six mutant variants (Y3A, S50A, Q53A, D55A, E57A and I59A), designed
based on molecular simulations, were expressed in Pichia pastoris. The proteins were refolded and purified to
homogeneity as monomers by gel filtration and anion exchange chromatography. The anti-thrombin activity of
the six mutants and RGD-hirudin was tested. Further, we evaluated the binding of the mutant variants and
RGD-hirudin to thrombin using BIAcore surface plasmon resonance analysis (SPR). Kinetics and affinity constants
showed that the KD values of all six mutant proteins were higher than that of RGD-hirudin.
Conclusions: These findings contribute to a novel understanding of the interaction between RGD-hirudin and
thrombin.
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A highly specific thrombin inhibitor derived from the
leech (Hirudomedicinalis hirudin) has come into use
over the past decade in in vitro blood research. It blocks
the thrombin-mediated conversion of fibrinogen to fi-
brin during clot formation, but unlike heparin, it is a
direct thrombin inhibitor (DTI) [1] that is not inacti-
vated by platelet factor 4 (PF4) [2,3].
A previous study has shown that the inhibitor is a
small peptide (65 amino acids, 7 kDa) that binds to ac-
tive thrombin and irreversibly inactivates it [4]. It has
also been thoroughly characterized in several labora-
tories by biochemical and biophysical means, including* Correspondence: weimo1025@shmu.edu.cn
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structures in solution of both natural and recombinant
variants [5-7]. These investigations revealed that hirudin
comprises an N-terminal globular domain (residues
Ile1-Ile49) stabilized by three disulfide bonds with [1-5,4-6]
connectivity, which spontaneously folds in solution [8].
This compact domain is extended on the C-terminus by a
short acidic tail that lacks cysteine residues and is
essentially disordered in solution [9]. Structural studies
conducted on hirudin in the free [5-7,10] and thrombin-
bound state [11,12] indicate that both the N-terminus
(Tyr3, Asp5) [11,13] and the C-terminus play an important
role in the interaction with thrombin. Notably, the long,
extended conformation of the C-terminus interacts with a
multitude of residues on the surface of thrombin.
The novel recombinant RGD-hirudin, which contains
an Arg-Gly-Asp (RGD) adhesion site recognition se-
quence, is a bi-functional molecule based on the structureThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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version, several amino acid residues in the C-terminus
have been replaced by negatively charged residues (Asp62
and Asp65). Asp53 was mutated to Gln53, Glu58 was
mutated to Pro58, and Glu66 was added. These changes
improve the hydrophobicity of the protein and allow the
recombinant RGD-hirudin to interact more effectively
with the fibrinogen recognition exosite of thrombin, re-
sulting in a specific activity of 12,000 ATU/mg [15]. Given
these changes, we hypothesized that the interaction bet-
ween RGD-hirudin and thrombin would be similar to that
between wild-type hirudin and thrombin. To test this, we
expressed and purified RGD-hirdudin and six mutant va-
riants in Pichia pastoris. The design of the six mutations
was based on molecular simulations. The Titration Testing
Method and BIAcore® surface plasmon resonance analysis
(SPR) were used to test their thrombin inhibition activity.




Accelrys Discovery Studio (DS, version 3.1) was used for
homology modeling (MODELER) [16] and docking simu-
lation (ZDOCK) [17,18]. Pichia pastoris cells carrying the
RGD-hirudin gene (Mut+) and pPIC9k-RGD-hirudin plas-
mid were stored in our lab. Briefly, the RGD-hirudin gene
was synthesized in the Key Laboratory of Molecular Medi-
cine at Fudan University. cDNA encoding RGD-hirudin
was cloned into the plasmid pPIC9K, and this expression
vector was transformed into Pichia pastoris GS115. Vec-
tor integration into the Pichia pastoris chromosome was
confirmed by PCR [14,19]. DNA primers were synthesized
by Sangon Biotech (Shanghai) Co., Ltd. The Site-Directed
Mutagenesis Kit was purchased from SBS Genetech Co.,
Ltd. Yeast nitrogen base was obtained from Sigma Aldrich
Co., Ltd. Blood plasma was obtained from the Shanghai
Blood Center. Sephacryl S-100 HR, Sephadex-G50, and
Q-Sepharose-FF were purchased from GE Healthcare Co.,
Ltd. The Biacore T100 instrument and research grade
CM5 chips were purchased from Biacore (GE Healthcare)
Co., Ltd. Other reagents were of analytical purity.
Homology modeling
The amino acid sequence of RGD-hirudin was obtained in
our lab. The NCBI protein BLAST program was used to
search the Protein Data Bank (PDB) and was used to se-
lect a template structure for RGD-hirudin homology mo-
deling. From the selected templates, a three-dimensional
model of RGD-hirudin was obtained by homology mo-
deling using the software package Discovery Studio 3.1.
Constructed models were refined by performing an opti-
mized geometry calculation of the mechanics using aug-
mented CHARMM in Discovery Studio 3.1. The qualityof refined models was assessed on the basis of both geo-
metry and energy. The stereo-chemical properties of the
models were investigated with a Ramachandran plot using
PROCHECK [20].
Protein-protein docking
To assess the interaction between RGD-hirudin and
thrombin, docking the modeled structure of RGD-hirudin
with the crystal structure of thrombin (PDB ID: 4HTC)
chain H&L was performed. ZDOCK tested the different
docking sites by moving the ligand around the receptor.
To obtain more accurate predictions, we specified the an-
gular step size for the rotational sampling of the ligand
orientations as 6, and the shape complementarity, desol-
vation and electrostatic energy terms were used in the
initial-stage ranking of the docked protein poses. The
docking parameters are set as follow: Input Receptor
Protein: 4HTC: Thrombin, Input Ligand Protein: RGD-
Hirudin, Angular Step Size: 6, ZRank: True, Clustering:
Top poses: 2000, RMSD Cutoff: 6, Interface Cutoff: 9,
Maximum Number of Clusters: 60.
Mutation Energy Calculation (binding affinity)
The Mutation Energy Calculation was used to evaluate
the effect of single-point mutations on the binding af-
finity in the RGD-hirudin-thrombin docking complex.
This protocol performs amino acid scanning muta-
genesis on a set of residues (selected according to the
docking results) by mutating each to alanine. The energy
effect on the binding affinity of each mutation (Mutation
Energy) was calculated as the difference in the binding
free energy between the mutant and wild-type proteins.
The binding free energy is defined as the difference in
the free energy between the complexed and unbound
state. All interaction energy terms were calculated by
CHARM using a Generalized Born implicit solvent
model; these terms contained empirically scaled contri-
butions of van der Waals and electrostatic interactions
and a non-polar solvation energy term. The mutation
energy function contained also a side chain entropy
term. The temperature was set at 37°C. This process was
also implemented with the software package Discovery
Studio 3.1.
Cloning, expression, and purification of RGD-hirudin and
the mutant variants
For preparation of six RGD-hirudin mutants, a Site-
Directed Mutagenesis Kit was using two complementary
primers which were described as follows (Table 1) and
the pPIC9k-RGD-hirudin plasmid as a template. The
procedure consisted of 18 polymerase chain reaction cy-
cles as specified by the manufacturer’s manual using Pfu
polymerase. The mutated construct was then digested
with the restriction enzyme DpnI, which is specific to















*Sense primer-5′; anti-sense primer-3′; all mutations are in bold letters.
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plate and select mutation-containing newly-synthesized
DNA. DNA sequencing confirmed that all six mutant
plasmids were correct.
Wild type and mutant variants of RGD-hirudin were
expressed in Pichia pastoris, then purified by gel filtration
and anion exchange chromatography as previously de-
scribed [14,21]. Briefly, a single colony was used to inocu-
late 5 mL of YPD in a 50 mL flask, which was incubated
for 14 h at 30°C at 220 rpm. This culture was used to in-
oculate 200 mL of sterile BMGY. Cultures were incubated
at 30°C and 220 rpm for 30 h to an OD600 of 5.8. Cells were
harvested by centrifugation at 3000 rpm for 30 min, washed
with 100 mM potassium phosphate (pH 6.0), and carefully
resuspended in 200 mL sterile BMM. Samples were incu-
bated at 30°C for another 72 h, with pulses of 0.5% (v/v)
methanol added every 12 h. The culture was centrifuged
and the supernatant was loaded onto a Sephacryl-S100
column (7.5 cm× 80 cm), pre-equilibrated with 20mMol/L
phosphate buffer (PB, pH 7.4). A sample of 400 mL was
eluted from the gel filtration column and loaded onto a
Q-Sepharose FF column (2.6 cm× 20 cm), also pre-
equilibrated with 20mMol/L PB (pH 7.4). The column was
washed with 20mMol/L PB (pH 7.4), followed by a single
linear gradient of 0–1.0Mol/L NaCl-PB buffer. RGD-
hirudin was eluted at 0.25Mol/L NaCl-PB. The sample that
showed anti-thrombin activity was collected and desalted
with a Sephadex-G50 column (1.6 cm× 20 cm). Loading
sample volumes were standardized to 5 mL. Protein con-
centration was measured with the Bradford assay. The
desalted samples were lyophilized and stored at −80°C.
Protein identification
Protein samples (wild type and mutant variants of RGD-
hirudin) were analyzed by 15% SDS-PAGE. The anti-thrombin activity of RGD-hirudin and the mutant variants
was tested by the Titration Testing Method, according to
Markwardt [22]. Briefly, 200 mL of fresh plasma was
added to a 1.5 mL tube. A 5 mL sample of RGD-hirudin
was added to the plasma and mixed by vortexing. Throm-
bin (5 mL of 100 NIH units) was added and allowed to
stand for 1 min at 37°C. If the plasma did not clot, the
RGD-hirudin contained 100 units of anti-thrombin ac-
tivity. Thus, consumption of 1 NIH unit of thrombin is
equivalent to 1 unit of anti-thrombin activity. A classic
turbidity assay was used to measure the anti-platelet ag-
gregation activity of RGD-hirudin and the mutant variants
[15]. Aggregation of rabit platelets in response to an-
tagonists was analyzed using lumi-aggregometer (Model
400VS, Chrono-Log, Haverston, PA, USA).
Surface plasmon resonance interaction analysis (BIAcore)
Thrombin was diluted in 5mMol/L sodium acetate
(pH 5.0), and 2000 response units were immobilized via
amine coupling to CM5 sensor chip flow chambers (GE
Healthcare). Briefly, proteins were mixed with equal vo-
lumes of freshly prepared 100mMol/L N-hydroxysuccini-
mide and 400mMol/L N-ethyl-N’-(dimethylaminopropyl)
carbodiimide, and capping of unreacted carboxymethyl
sites was achieved by injection of 1.0Mol/L ethanolamine,
pH 7.0. A flow chamber was subjected to the immo-
bilization protocol. RGD-hirudin and the six mutant vari-
ants were sequentially diluted in running buffer (10mMol/
L HEPES, 150mMol/L NaCl, 0.005% Surfactant P20 (BIA-
core), pH 7.5) and injected over the surfaces at dif-
ferent concentrations (RDG-hirudin: 0-50nMol/L; Y3A:
0-10mMol/L; S50A: 0-50nMol/L; Q53A: 0-5μMol/L;
D55A: 0-10μMol/L; E57A: 0-10μMol/L; I59A: 0-50μMol/L)
at 30 μL/min.
Binding was monitored with a BIAcore T100 instru-
ment. Between experiments, the surfaces were strictly
regenerated with multiple pulses of 2Mol/L NaCl and
1.5Mol/L glycine-HCl, pH 2.5, followed by an extensive
wash procedure with running buffer.
After x- and y-axis normalization of the data obtained,
the blank bulk refraction curves from the control flow
chamber of each injected concentration were subtracted.
Binding curves were displayed, and the association (Ka)
and dissociation (Kd) rate constants were determined
using the BIAevaluation 4.1 software and its equation
for 1:1 Langmuir binding. From these values, affinities
(KD) were calculated.
Results
Molecular modeling of RGD-hirudin
RGD-hirudin was molecularly modeled, based on the
crystal structure of hirudin variant 2 from chain I of the
hirudin-thrombin complex (PDB ID: 4HTC) [23] and
the NMR solution structure of chain A of recombinant
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and chain A shares 100% sequence identity with RGD-
hirudin. Residues 52–66 of the structure, which may play
important roles in the interaction with thrombin, were ab-
sent. The sequence alignment is shown in Figure 1A. The
three-dimensional structural model for RGD-hirudin was
generated based on the 4HTC and 2JOO templates using
the Discovery Studio 3.1 software.
Analysis of the Ramachandran plot of the refined
model showed that 96.9% of the residues lie in the most
favorable regions (Figure 1B), which indicates that the
model is suitable for structural studies (Figure 1C).
Thrombin docked with RGD-hirudin
The docking simulation of RGD-hirudin and thrombin
resulted in 54000 poses for analysis. The poses were
clustered with the cluster root-mean-square deviation
(RMSD) cutoff and the interface cutoff both set to 10
angstroms. For a pose to be included in a cluster, the
RMSD cutoff was the maximal RMSD of the ligand
interface from the cluster center, and the interface cutoff
was the size of the interface region between receptor
and ligand. Poses were then re-ranked with Van DerFigure 1 Molecule simulation of RGD-hirudin. (A) Amino acid sequence
thrombin complex (PDB ID: 4HTC) and the NMR solution structure of chain A o
selected RGD-hirudin model. The distribution of the RGD-hirudin residues (black
generously allowed (light yellow), and disallowed (white) regions. (C) HomologyWaals, desolvation and electrostatics energy terms. The
best docking poses were selected, based on a higher
dock score combined with certain types of interactions
between hirudin variant 2 and thrombin. We hypo-
thesized that the interaction between RGD-hirudin and
thrombin is similar to that of hirudin variant 2 and
thrombin, and therefore favored this type of interaction.
Finally, pose 24 was chosen as the best docking complex
(Figure 2A). A close examination of the region in the
functional site of RGD-hirudin when in complex with
thrombin revealed that Tyr3 in the N-terminus of RGD-
hirudin formed one hydrogen bond with Gly210 of
thrombin. Further, in the C-terminus of RGD-hirudin,
Ser50 formed two hydrogen bonds with Glu192 of throm-
bin, Gln53 formed one hydrogen bond with Leu40 of
thrombin, Asp55 formed two hydrogen bonds with Arg73
of thrombin, and both Glu57 and Ile59 were hydrogen-
bonded to Gln38 of thrombin (Figure 2B).
Calculating the effect of single-point mutations on
binding affinity
We performed amino acid scanning mutagenesis of
RGD-hirudin-thrombin complexes, mutating to alaninealignment of RGD-hirudin, chain I of hirudin variant 2 from the hirudin-
f recombinant RGD-hirudin (PDB ID: 2JOO). (B) Ramachandran plot of the
dots) are shown in color: most favorable (red), additional allowed (yellow),
modeling of the RGD-hirudin structure.
Figure 2 Thrombin docked with RGD-hirudin. Thrombin is
represented by its solvent-accessible surface, while hirudin is shown
as a solid ribbon. (A) The best docking complex of RGD-hirudin and
thrombin (pose 24). (B) Close-up of the region of the RGD-hirudin
functional site in complex with thrombin. Residues of RGD-hirudin
are in yellow. Residues of thrombin are in blue. Hydrogen bond
interactions are indicated with dashed green lines.
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important. We then calculated the differences in the free
energy of binding between the wild-type and mutated
structures. The results showed that the binding affinity
of the six single-point mutations with thrombin were
weaker (weighted mutation energy greater than zero)
than that of wild-type RGD-hirudin with thrombin. TheTable 2 Calculate the effect of single-point mutations on the
Residues Mutation VDW Term Electrostatic Term Entropy T
Tyr3 Ala 6.58 -1.92 0.12
Ser50 Ala 6.68 0.41 -0.58
Gln53 Ala 8.99 -0.47 -2.02
Asp55 Ala 8.7 3.15 -0.94
Glu57 Ala 0.72 1.78 -0.13
Ile59 Ala 3.19 -0.4 -0.58
VDW Term: The van der Waals contribution to the binding energy differences.
Electrostatic Term: The electrostatic contribution to the binding energy difference
Entropy Term: The side-chain entropy contribution to the binding energy differenc
Non-polar Term: The non-polar (surface tension) contribution to the binding energ
Weighted Mutation Energy: The total free energy difference between the wild typ
Electrostatic, Entropy and Non-polar terms.effect of each mutation was destabilizing (Table 2), which
further confirmed the docking results and demonstrates
that the six residues (Tyr3, Ser50, Gln53, Asp55, Glu57,
Ile59) of RGD-hirudin might participate in the interaction
with thrombin.
Purification and characterization of RGD-hirudin and
mutant variants
In this study, we focused on the residues of RGD-hirudin
that are hydrogen-bonded to thrombin. These six residues
(Tyr3, Ser50, Gln53, Asp55, Glu57, Ile59) were mutated to
Ala, and the proteins were purified by gel filtration and
anion exchange chromatography, as described in the
Materials and Methods. The average yields of pure protein
from 200 mL of fermentation culture were: RGD-hirudin,
46 mg; Y3A, 50 mg; S50A, 42 mg; Q53A, 47 mg; D55A,
40 mg; E57A, 38 mg; and I59A, 55 mg (Figure 3A).
The anti-thrombin specific activity of the purified RGD-
hirudin was almost 18000 ATU/mg, while the mutated ver-
sions had activities reduced to different degrees: Y3A, 4000
Anti-thrombin Units (ATU)/mg; S50A, 16000 ATU/mg;
Q53A, 14000 ATU/mg; D55A, 12000 ATU/mg; E57A,
11000 ATU/mg; and I59A, 9000 ATU/mg (Figure 3B). The
dramatic decline in anti-thrombin specific activity of the
Y3A mutation suggests that Tyr3 in RGD-hirudin might be
a very important residue for its interaction with thrombin.
Anti-platelet aggregation activities of the proteins were
determined by a classic turbidity assay. The results showed
there was no significant difference between RGD-hirudin
and the mutant variants (Figure 3C).
SPR measurement of the interactions of RGD-hirudin and
six mutant variants with thrombin
To further analyze the binding properties of the six
mutant variants of RGD-hirudin with thrombin and to
establish the affinity constant of the binding, surface
plasmon resonance analysis was performed. The binding
activity of RGD-hirudin was compared with those of the
six mutants (Y3A, S50A, Q53A, D55A, E57A and I59A)binding affinity









between wild type and mutated structures.
es.
y differences.
e and mutated structures. It is calculated as a weighted sum of the VDW,
Figure 3 Expression, purification and characteristic of RGD-hirudin and six mutant versions. (A) Expression and purification of RGD-hirudin
and six mutant versions were analyzed by 15% SDS-PAGE. Lane M: molecular mass standards (116 to 14.4 kDa) 20 μL (1 mg/mL) of each sample was
loaded on the gel. (B) Anti-thrombin activity of purified RGD-hirudin and six mutant variants. (C) RGD-hirudin and the six mutants have similar effects on
rabbit platelet aggregation induced by ADP. The experiments were performed five times with similar results. Error bars represent the standard deviation.
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thrombin as a receptor. The KD (affinity) was calculated
from the determined Ka and Kd values (Table 3). The KD
for the interaction between RGD-hirudin and thrombin
was 15.5nM (Figure 4A), whereas the KD of thrombin
binding for the mutant Y3A was 3.6 mM; S50A, 35nM;
Q53A, 0.57 μM; D55A, 1 μM; E57A, 2.4 μM; and I59A,
19 μM (Figure 4B-G). BIAcore analysis thus confirmed
that the binding affinity of thrombin and wild-type
RGD-hirudin is slightly stronger than that of the S50A
mutant, and much stronger than those of the other fiveTable 3 Kinetics and affinity constants for RGD-hirudin











RGD-hirudin 1.77 × 103 2.73 × 10−5 1.55 × 10−8
Y3A 0.80 2.88 × 10−3 3.61 × 10−3
S50A 1.12 × 103 3.94 × 10−5 3.50 × 10−8
Q53A 59.20 3.37 × 10−5 5.70 × 10−7
D55A 371.00 3.83 × 10−4 1.03 × 10−6
Q57A 155.00 3.74 × 10−4 2.41 × 10−6
I59A 73.00 1.39 × 10−3 1.90 × 10−5variants, especially Y3A. Meanwhile, the affinity curves
of RGD-hirudin and the six mutants (at the same mo-
larity of 100nM) and thrombin demonstrated that the
binding affinities for thrombin of all six mutant versions
were weaker than that of RGD-hirudin (Figure 4H). In
conclusion, the six residues (Tyr3, Ser50, Gln53, Asp55,
Glu57 and Ile59) are important for binding to thrombin,
as each mutant protein binds with lower affinity than
wild-type RGD-hirudin.
Discussion
Hirudin, an antithrombotic substance produced by the
salivary glands of the medicinal leech (Hirudomedicinalis)
[25,26], is the most potent and specific thrombin inhibitor
currently known. It acts by binding directly via multiple
sites to thrombin: the N-terminal globular domain binds
near to the active site of thrombin, while the extended
C-terminal segment, which is abundant in acidic residues
and includes a sulfated tyrosine, has both ionic and hydro-
phobic interactions with the thrombin fibrinogen recogni-
tion exosite (FRE) [23].
In our laboratory, a new type of recombinant RGD-
hirudin has been successfully cloned, expressed in the
methylotrophic yeast Pichia pastoris and subsequently
purified. It may be a more effective agent than wild-type
Figure 4 SPR measurement of the interactions of RGD-hirudin and mutant variants with thrombin. (A-G) KD values. BIAcore analysis
showed that the binding affinity of thrombin and wild-type RGD-hirudin was slightly stronger than those of the six mutants. (H) Affinity curves
(with proteins at 100nM) demonstrated that the binding affinities of thrombin and the six mutants were weaker than that of RGD-hirudin.
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post-anastomosis surgery. We propose that RGD-
hirudin will be able to replace heparin or wild-type
hirudin and reduce bleeding rates, due to its bi-
functional action at a much lower dosage than wild-
type hirudin [15]. However, RGD-hirudin needed to be
modified to reduce the molecular weight to be suitablefor advanced oral administration, rather than intraven-
ous injection.
Although our lab has previously conducted a study on
the structure of RGD-hirudin in solution (1–49) [24], the
structure of the extended C-terminal domain (from Asn52
to Glu66), which is essential for the hirudin-thrombin inter-
action, had not yet been determined. The overall structure
Huang et al. BMC Structural Biology  (2014) 14:26 Page 8 of 9of RGD-hirudin (1–66) developed above used the crystal
structure of chain I of hirudin variant 2 from the hirudin-
thrombin complex (PDB ID: 4HTC) and the NMR solution
structure of chain A of recombinant RGD-hirudin (PDB
ID: 2JOO) as templates for docking with thrombin. Based
on the docking model and the structural characteristics of
the RGD-hirudin-thrombin complex, we find that the
mechanism of interaction is consistent with that of native
hirudin and thrombin. In this interaction, the globular N-
terminal domains interact with the active site of thrombin,
while the anionic C-terminal tails bind to exosite 1 on
thrombin (the substrate-binding site) [27]. Six residues
(Tyr3, Ser50, Gln53, Asp55, Glu57 and Ile59) of RGD-hirudin
are hydrogen-bonded to thrombin, according to the results
of simulations. To validate these residues as functional sites,
mutant variants were constructed. Anti-thrombin activity
assays and surface plasmon resonance analysis were also
performed. Previous studies have indicated that the first
three residues in the N-terminus of hirudin represent about
30% of the binding energy [28] and the acidic C-terminal
segment accounts for about 32% of the binding energy at
zero ionic strength [29]. Mutagenesis studies have shown
that all the negatively charged residues of the C-terminal
tail are relevant for complex formation [30-32]. Our results
imply that RDG-hirudin’s N-terminus (Tyr3) and C-
terminus (Ser50, Gln53, Asp55, Glu57 and Ile59) are both cru-
cial for inhibiting the activity of thrombin, for binding near
its active site and forming hydrogen bonds with exosite I.
In this study, we focused on hydrogen bonding inter-
actions between RGD-hirudin and thrombin. However,
hydrophobic interactions, Van der Waals interactions,
and salt bridges might be also exist. For example, the
phenyl ring of Phe56 engages in strong Van der Waals,
edge-to-face interactions with thrombin Phe34, according
to our docking complex (data not shown). Thus, other
mechanisms of interacting and binding should be inves-
tigated in the future.Conclusions
In summary, The purpose of this study is that we found
the binding site and active centre of RGD-Hirduin. In
future, these results might be useful to provide a struc-
tural basis for the redesign of lower molecular weight
antithrombin peptides which would be developed to the
new oral drugs to fight thrombotic diseases.
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